ENvue Medical entered into a Secured Promissory Note and Security Agreement with Alpha Capital Anstalt for financing of up to $1,000,000, secured by substantially all company assets. The lender funded an initial tranche of $250,000 on October 8, 2026. Interest accrues at 10% per annum, with the principal and accrued interest due December 31, 2026, subject to extension options through December 31, 2028. Concurrently, the company amended its Series X Non-Voting Convertible Preferred Stock terms via an agreement with holders of at least 70% of outstanding shares. The amendment lowers the conversion price to $0.50 per share and adjusts provisions for subsequent dilutive equity issuances. ENvue Medical operates in the healthcare technology sector, providing software solutions for medical practices.
